GlassScriptPhysician profile
Satyaprasad Alapati
NPI 1679549695
$1,383.08
in general payments reported to CMS, 2019-2025
23 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.05 · 2020: $83.48 · 2021: $218 · 2022: $251 · 2023: $227 · 2024: $161 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $311.45 | 2019-2025 | Tremfya |
| Abbvie INC. | $288.43 | 2021-2025 | Humira, Rinvoq, Skyrizi |
| Genzyme Corporation | $136.19 | 2022-2025 | |
| Pfizer INC. | $123.66 | 2024-2025 | |
| Micro-Tech Endoscopy USA, INC. | $108.33 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $96.63 | 2023 | Utaswako Afp-L3 |
| Mirum Pharmaceuticals, INC. | $71.52 | 2025 | Livmarli |
| Takeda Pharmaceuticals U.S.A., INC. | $48.59 | 2020-2024 | Entyvio |
| Amgen INC. | $36.50 | 2022-2023 | Avsola, Amjevita |
| Regeneron Healthcare Solutions, INC. | $36.26 | 2025 | Dupixent |
| Olympus America INC. | $19.83 | 2019 | |
| Allergan, INC. | $18.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.43 | 2023 | Trulance |
| Cumberland Pharmaceuticals, INC. | $15.15 | 2020 | |
| Gilead Sciences, INC. | $14.77 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $14.70 | 2025 | Wegovy |
| Ardelyx, INC. | $14.16 | 2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $11.90 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,123.46 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satyaprasad Alapati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.